Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice

Journal of Immunology

Volumn 175, Issue 9, 2005, Pages 5649-5655

  Boar Jordan, Hélène ^a   Thompson, Heather L ^a   Bluestone, Jeffrey A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; AUTOIMMUNE NEUROPATHY; AUTOIMMUNE PERIPHERAL NEUROPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED STUDY; CYTOTOXICITY; DEMYELINATION; DIABETES MELLITUS; DISEASE ASSOCIATION; EFFECTOR CELL; EXPERIMENTAL MODEL; GUILLAIN BARRE SYNDROME; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; INTERFERON PRODUCTION; MOLECULAR BIOLOGY; MOUSE; MOUSE STRAIN; NERVE INJURY; NEUROPATHY; NONHUMAN; OBESITY; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

EID: 27144471025     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.9.5649     Document Type: Article

References (54)

1. Robinson, C. P., S. Yamachika, D. I. Bounous, J. Brayer, R. Jonsson, R. Holmdahl, A. B. Peck, and M. G. Humphreys-Beher. 1998. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum. 41: 150-156.
2. Krug, J., A. J. Williams, P. E. Beales, I. Doniach, E. A. Gale, and P. Pozzilli. 1991. Parathyroiditis in the non-obese diabetic mouse-a new finding. J. Endocrinol. 131: 193-196.
3. Salomon, B., L. Rhee, H. Bour-Jordan, H. Hsin, A. Montag, B. Soliven, J. Arcella, A. M. Girvin, S. D. Miller, and J. A. Bluestone. 2001. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J. Exp. Med. 194: 677-684.
4. Bour-Jordan, H., B. L. Salomon, H. L. Thompson, G. L. Szot, M. R. Bernhard, and J. A. Bluestone. 2004. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J. Clin. Invest. 114: 979-987.
5. Maurer, M., and R. Gold. 2002. Animal models of immune-mediated neuropathies. Curr. Opin. Neurol. 15: 617-622.
6. Kieseier, B. C., R. Kiefer, R. Gold, B. Hemmer, H. J. Willison, and H. P. Hartung. 2004. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131-156.
7. Winer, S., I. Astsaturov, R. Cheung, L. Gunaratnam, V. Kubiak, M. A. Cortez, M. Moscarello, P. W. O'Connor, C. McKerlie, D. J. Becker, and H. M. Dosch. 2001. Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens: nonimmunized nonobese diabetic mice can develop autoimmune encephalitis. J. Immunol. 166: 2831-2841.
8. Winer, S., H. Tsui, A. Lau, A. Song, X. Li, R. K. Cheung, A. Sampson, F. Afifiyan, A. Elford, G. Jackowski, D. J. Becker, P. Santamaria, P. Ohashi, and H. M. Dosch. 2003. Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive. Nat. Med. 9: 198-205.
9. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201: 723-735.
10. Maurer, M., K. V. Toyka, and R. Gold. 2002. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul. Disord. 12: 405-414.
11. Weishaupt, A., W. Bruck, T. Hartung, K. V. Toyka, and R. Gold. 2001. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α. Neurosci. Lett. 306: 77-80.
12. Zhu, J., E. Mix, and H. Link. 1998. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre syndrome. J. Neuroimmunol. 84: 40-52.
13. Zhu, W., E. Mix, and J. Zhu. 2003. Inflammation and proinflammatory cytokine production, but no demyelination of facial nerves, in experimental autoimmune neuritis in Lewis rats. J. Neuroimmunol. 140: 97-101.
14. Zhu, J., X. F. Bai, E. Mix, and H. Link. 1997. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 β, IL-6, IL-10, IL-12, TNF-α, TNF-β and cytolysin. Clin. Immunol. Immunopathol. 84: 85-94.
15. Zhu, Y., H. G. Ljunggren, E. Mix, H. L. Li, P. van der Meide, A. M. Elhassan, B. Winblad, and J. Zhu. 2001. Suppression of autoimmune neuritis in IFN-γ receptor-deficient mice. Exp. Neurol. 169: 472-478.
16. Bao, L., J. U. Lindgren, P. van der Meide, S. Zhu, H. G. Ljunggren, and J. Zhu. 2002. The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol. 12: 420-429.
17. Bao, L., J. U. Lindgren, Y. Zhu, H. G. Ljunggren, and J. Zhu. 2003. Exogenous soluble tumor necrosis factor receptor type I ameliorates murine experimental autoimmune neuritis. Neurobiol. Dis. 12: 73-81.
18. Conti, G., E. Scarpini, A. Rostami, S. Livraghi, P. L. Baron, D. Pleasure, and G. Scarlato. 1998. Schwann cell undergoes apoptosis during experimental allergic neuritis (EAN). J. Neurol. Sci. 161: 29-35.
19. Srinivasan, S., M. J. Stevens, H. Sheng, K. E. Hall, and J. W. Wiley. 1998. Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells. J. Clin. Invest. 102: 1454-1462.
20. Pittenger, G. L., D. Liu, and A. I. Vinik. 1997. The apoptotic death of neuroblastoma cells caused by serum from patients with insulin-dependent diabetes and neuropathy may be Fas- mediated. J. Neuroimmunol. 76: 153-160.
21. Chervonsky, A. V., Y. Wang, F. S. Wong, I. Visintin, R. A. Flavell, C. A. Janeway, Jr., and L. A. Matis. 1997. The role of Fas in autoimmune diabetes. Cell 89: 17-24.
22. Kagi, D., B. Odermatt, P. Seiler, R. M. Zinkemagel, T. W. Mak, and H. Hengartner. 1997. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J. Exp. Med. 186: 989-997.
23. Serreze, D. V., H. D. Chapman, C. M. Post, E. A. Johnson, W. L. Suarez-Pinzon, and A. Rabinovitch. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166: 1352-1359.
24. Hultgren, B., X. Huang, N. Dybdal, and T. A. Stewart. 1996. Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45: 812-817.
25. Tisch, R., B. Wang, and D. V. Serreze. 1999. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J. Immunol. 163: 1178-1187.
26. Su, X., Q. Hu, J. M. Kristan, C. Costa, Y. Shen, D. Gero, L. A. Matis, and Y. Wang. 2000. Significant role for Fas in the pathogenesis of autoimmune diabetes. J. Immunol. 164: 2523-2532.
27. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
28. Singer, G. G., A. C. Carrera, A. Marshak-Rothstein, C. Martinez, and A. K. Abbas. 1994. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol. 6: 913-920.
29. Serreze, D. V., M. A. Pierce, C. M. Post, H. D. Chapman, H. Savage, R. T. Bronson, P. B. Rothman, and G. A. Cox. 2003. Paralytic autoimmune myositis develops in nonobese diabetic mice made Th1 cytokine-deficient by expression of an IFN-γ receptor β-chain transgene. J. Immunol. 170: 2742-2749.
30. Zhu, J., H. Link, E. Mix, T. Olsson, and W. X. Huang. 1994. Th1-like cell responses to peripheral nerve myelin components over the course of experimental allergic neuritis in Lewis rats. Acta Neurol. Scand. 90: 19-25.
31. Zhu, J., E. Mix, T. Olsson, and H. Link. 1994. Cellular mRNA expression of interferon-γ, IL-4 and transforming growth factor-β (TGF-β) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin. Exp. Immunol. 98: 306-312.
32. Yu, S., Z. Cheh, E. Mix, S. W. Zhu, B. Winblad, H. G. Ljunggren, and J. Zhu. 2002. Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J. Neuropathol. Exp. Neurol. 61: 614-622.
33. Creange, A., L. Belec, B. Clair, J. C. Raphael, and R. K. Gherardi. 1996. Circulating tumor necrosis factor (TNF)-α and soluble TNF-γ receptors in patients with Guillain-Barre syndrome. J. Neuroimmunol. 68: 95-99.
34. Hohnoki, K., A. Inoue, and C. S. Koh. 1998. Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 87: 27-32
35. Ossege, L. M., E. Sindern, B. Voss, and J. P. Malin. 2000. Expression of TNFα and TGFβ1 in Guillain-Barre syndrome: correlation of a low TNFα-/TGFβ1-mRNA ratio with good recovery and signs for immunoregulation within the cerebrospinal fluid compartment. Eur. J. Neurol. 7: 17-25.
36. Jander, S., and G. Stoll. 2001. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 114: 253-258.
37. Misawa, S., S. Kuwabara, M. Mori, N. Kawaguchi, Y. Yoshiyama, and T. Hattori. 2001. Serum levels of tumor necrosis factor-α in chronic inflammatory demyelinating polyneuropathy. Neurology 56: 666-669.
38. Lindenlaub, T., and C. Sommer. 2003. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol. 105: 593-602.
39. Dahle, C., C. Ekerfelt, M. Vrethem, M. Samuelsson, and J. Ernerudh. 1997. T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barre syndrome. J. Neurol. Sci. 153: 54-60.
40. Dahle, C., M. Kvarnstrom, C. Ekerfelt, M. Samuelsson, and J. Ernerudh. 2003. Elevated number of cells secreting transforming growth factor β in Guillain-Barre syndrome. APMIS 111: 1095-1104.
41. Aarli, J. A. 2003. Role of cytokines in neurological disorders. Curr. Med. Chem. 10: 1931-1937.
42. Van Doorn, P. A., and L. Ruts. 2004. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr. Opin. Neurol. 17: 607-613.
43. Goto, H., H. Matsuo, S. Nakane, H. Izumoto, T. Fukudome, C. Kambara, and N. Shibuya. 2001. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther. Apher. 5: 494-496.
44. Dalakas, M. C. 2004. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther. 102: 177-193.
45. Munoz-Fernandez, M. A., and M. Fresno. 1998. The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol. 56: 307-340.
46. Probert, L., K. Akassoglou, M. Pasparakis, G. Kontogeorgos, and G. Kollias. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α. Proc. Natl. Acad. Sci. USA 92: 11294-11298.
47. Fontaine, V., S. Mohand-Said, N. Hanoteau, C. Fuchs, K. Pfizenmaier, and U. Eisel. 2002. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 22: RC216.
48. Marchetti, L., M. Klein, K. Schlett, K. Pfizenmaier, and U. L. Eisel. 2004. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation: essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-κB pathway. J. Biol. Chem. 279: 32869-32881.
49. Romera, C., O. Hurtado, S. H. Botella, I. Lizasoain, A. Cardenas, P. Fernandez-Tome, J. C. Leza, P. Lorenzo, and M. A. Moro. 2004. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-α pathway. J. Neurosci. 24: 1350-1357.
50. Vence, L., C. Benoist, and D. Mathis. 2004. Fas deficiency prevents type 1 diabetes by inducing hyporesponsiveness in islet β-celI-reactive T-cells. Diabetes 53: 2797-2803.
51. Zetti, U. K., R. Gold, K. V. Toyka, and H. P. Hartung. 1996. In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat. Acta Neuropathol. 91: 360-367.
52. Wohlleben, G., S. M. Ibrahim, J. Schmidt, K. V. Toyka, H. P. Hartung, and R. Gold. 2000. Regulation of Fas and FasL expression on rat Schwann cells. Glia 30: 373-381.
53. Bonetti, B., P. Valdo, G. Ossi, L. De Toni, B. Masotto, S. Marconi, N. Rizzuto, E. Nardelli, and G. Moretto. 2003. T-cell cytotoxicity of human Schwann cells: TNFα promotes fasL-mediated apoptosis and IFN γ perforin-mediated lysis. Glia 43: 141-148.
54. Debray-Sachs, M., C. Carnaud, C. Boitard, H. Cohen, I. Gresser, P. Bedossa, and J. F. Bach. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFN γ. J. Autoimmun. 4: 237-248.